MTCH2 in Metabolic Diseases, Neurodegenerative Diseases, Cancers, Embryonic Development and Reproduction
DOI: https://doi.org/10.2147/dddt.s460448
IF: 4.3188
2024-06-13
Drug Design Development and Therapy
Abstract:Xiaoqing Peng, 1– 4, &ast Yuanyuan Yang, 3, 4, &ast Ruirui Hou, 1 Longbiao Zhang, 1 Can Shen, 3 Xiaoyan Yang, 3 Zhigang Luo, 5 Zongzhi Yin, 3, 4 Yunxia Cao 3, 4 1 School of Pharmacy, Anhui Medical University, Hefei, People's Republic of China; 2 Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, Hefei, Anhui, People's Republic of China; 3 Department of Obstetrics and Gynecology, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China; 4 The Key National Health Commission Key Laboratory of Study on Abnormal Gametes and Reproductive Tract (Anhui Medical University), Hefei, People's Republic of China; 5 Department of Cardiology, The First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yunxia Cao; Zongzhi Yin, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Sushan District, Hefei, Anhui, People's Republic of China, Email ; Mitochondrial carrier homolog 2 (MTCH2) is a member of the solute carrier 25 family, located on the outer mitochondrial membrane. MTCH2 was first identified in 2000. The development in MTCH2 research is rapidly increasing. The most well-known role of MTCH2 is linking to the pro-apoptosis BID to facilitate mitochondrial apoptosis. Genetic variants in MTCH2 have been investigated for their association with metabolic and neurodegenerative diseases, however, no intervention or therapeutic suggestions were provided. Recent studies revealed the physiological and pathological function of MTCH2 in metabolic diseases, neurodegenerative diseases, cancers, embryonic development and reproduction via regulating mitochondrial apoptosis, metabolic shift between glycolysis and oxidative phosphorylation, mitochondrial fusion/fission, epithelial-mesenchymal transition, etc. This review endeavors to assess a total of 131 published articles to summarise the structure and physiological/pathological role of MTCH2, which has not previously been conducted. This review concludes that MTCH2 plays a crucial role in metabolic diseases, neurodegenerative diseases, cancers, embryonic development and reproduction, and the predominant molecular mechanism is regulation of mitochondrial function. This review gives a comprehensive state of current knowledgement on MTCH2, which will promote the therapeutic research of MTCH2. Keywords: Mimp, MTCH2, mitochondrial carrier homolog 2, BID, apoptosis Graphical Mitochondrial carrier homolog 2 (MTCH2) is a member of the solute carrier 25 family, an integral membrane protein known for the role of catalyzing the exchange of substrates across the inner mitochondrial membrane (IMM). MTCH2 is primarily located on the outer mitochondrial membrane (OMM) rather than the IMM, and functions as an insertase 1 and also a scramblase. 2,3 The insertase allows the insertion of cytoplasmic α-helical protein into the outer mitochondrial membrane but not the transfer to the inner mitochondrial membrane. 1 The scramblase facilitates bidirectional lipid transport across cell membranes. 4 The best-known role of MTCH2 is binding with truncated BID (tBID) to regulate mitochondrial apoptosis. 5 Recent studies have demonstrated the physiological and pathological role of MTCH2 in metabolic diseases, neurodegenerative diseases, cancers, embryonic development and reproduction, and the predominant molecular mechanisms are regulating apoptosis, metabolic shift, mitochondrial elongation, epithelial-mesenchymal transition, etc. No review has summarised those findings with disease-oriented aspects, although a recent review article published in March 2024 concluded current studies on MTCH2 from a mechanism of action aspects. A thoughtful understanding of MTCH2 in health and diseases is helpful in guiding future research. Therefore, a total of 130 articles related to MTCH2 are systematically searched using PubMed databases, and the findings are summarised in this review. In the following sections, we will demonstrate the structure and pro-apoptosis role of MTCH2 and summarise the current studies of MTCH2 in metabolic diseases, neurodegenerative diseases, cancers, embryonic development and reproduction. Figure 1 Structure of MTCH2. ( A ) 303 amino acids of human MTCH2, red refers to the position cross-linking to cBID; yellow refers to the amino acids 123 to 206, which construct a mitochondrial carry domain; ( B ) the diagram of human MTCH2, yellow refers to the singl -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal